Investigational Drug Beats Clopidogrel At Stopping Stent Thrombosis In Trial
This article was originally published in The Gray Sheet
Executive Summary
Stent recipients taking Eli Lilly's prasugrel have fewer ischemic outcomes, including stent thrombosis, than those taking clopidogrel regardless of stent type, according to a subanalysis of the TRITON-TIMI 38 trial presented March 29 at the American College of Cardiology conference in Chicago
You may also be interested in...
Major Trials On Dual-Antiplatelet Therapy For DES In The Works
The four major drug-eluting stent manufacturers are negotiating the design of a clinical trial that will help determine the optimal duration of concomitant dual-antiplatelet therapy for patients with a drug-eluting stent, according to Boston Scientific
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.